Iatrogenic Takotsubo Cardiomyopathy Following Overdose Norepinephrine Administration During Percutaneous Coronary Intervention

Int Heart J. 2020 Nov 28;61(6):1298-1302. doi: 10.1536/ihj.20-118. Epub 2020 Oct 28.

Abstract

Takotsubo cardiomyopathy (TTC) is characterized by reversible ventricular dysfunction induced by endogenous and, occasionally, exogenous catecholamine. We present a report on a patient who developed TTC and cardiogenic shock during percutaneous coronary intervention (PCI) secondary to inadvertent norepinephrine administration. His hemodynamic status and cardiac function were totally restored within 1 week after hemodynamic support using intra-aortic balloon pump without sequela. Thus, TTC should be considered once a patient presents with symptoms mimicking acute coronary syndrome (ACS) after catecholamine administration.

Keywords: Cardiogenic shock; Catecholamine; Stress-induced cardiomyopathy.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / therapeutic use
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Bisoprolol / therapeutic use
  • Coronary Restenosis / surgery*
  • Creatine Kinase / blood
  • Creatine Kinase, MB Form / blood
  • Drug Overdose
  • Drug-Eluting Stents
  • Echocardiography
  • Humans
  • Hypotension / drug therapy*
  • Iatrogenic Disease
  • Intra-Aortic Balloon Pumping
  • Intraoperative Complications / drug therapy*
  • Male
  • Medication Errors*
  • Middle Aged
  • Norepinephrine / poisoning*
  • Percutaneous Coronary Intervention*
  • Recovery of Function
  • Shock, Cardiogenic / blood
  • Shock, Cardiogenic / chemically induced*
  • Shock, Cardiogenic / diagnosis
  • Shock, Cardiogenic / therapy
  • Stents
  • Stroke Volume
  • Takotsubo Cardiomyopathy / blood
  • Takotsubo Cardiomyopathy / chemically induced*
  • Takotsubo Cardiomyopathy / diagnostic imaging
  • Takotsubo Cardiomyopathy / therapy
  • Troponin I / blood
  • Valsartan / therapeutic use
  • Vasoconstrictor Agents / poisoning*

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Troponin I
  • Vasoconstrictor Agents
  • Valsartan
  • Creatine Kinase
  • Creatine Kinase, MB Form
  • Norepinephrine
  • Bisoprolol